Skip to main content

Published locations for Bezlotoxumab reduces CDI recurrence across antibiotic subgroups

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Bezlotoxumab reduces CDI recurrence across antibiotic subgroups

User login

  • Reset your password
  • /content/bezlotoxumab-reduces-cdi-recurrence-across-antibiotic-subgroups
  • /familypracticenews/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across
  • /gihepnews/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across-antibiotic
  • /ehospitalistnews/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across
  • /idpractitioner/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across
  • /internalmedicinenews/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across
  • /infectiousdisease/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across
  • /internalmedicine/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across
  • /familymedicine/article/117425/emerging-infections/bezlotoxumab-reduces-cdi-recurrence-across